NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $5.27 -0.21 (-3.83%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.21▼$5.5050-Day Range$5.11▼$9.4652-Week Range$1.96▼$9.97Volume1.70 million shsAverage Volume2.19 million shsMarket Capitalization$627.57 millionP/E RatioN/ADividend YieldN/APrice Target$8.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Humacyte alerts: Email Address Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside63.2% Upside$8.60 Price TargetShort InterestHealthy12.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 10 Articles This WeekInsider TradingSelling Shares$10.51 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.09) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.60 out of 5 starsMedical Sector412th out of 910 stocksBiological Products, Except Diagnostic Industry58th out of 155 stocks 3.4 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.42% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Humacyte has recently decreased by 5.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 1.9 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Humacyte this week, compared to 3 articles on an average week.Search InterestOnly 30 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,508,440.00 in company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($1.09) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Humacyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesSeptember 1, 2024 | insidertrades.comInsider Selling: Humacyte, Inc. (NASDAQ:HUMA) CFO Sells 39,389 Shares of StockSeptember 6 at 5:05 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives Buy Rating from BenchmarkSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... September 6 at 12:53 AM | markets.businessinsider.comBenchmark Co. Remains a Buy on Humacyte (HUMA)September 6 at 12:53 AM | benzinga.comHow Is The Market Feeling About Humacyte?September 4 at 1:19 AM | finance.yahoo.comHumacyte to Participate at Upcoming Investor Conferences in SeptemberSeptember 1, 2024 | americanbankingnews.comLaura E. Niklason Sells 277,090 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockSeptember 1, 2024 | americanbankingnews.comHumacyte, Inc. (NASDAQ:HUMA) Director Sells 352,112 SharesSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 31, 2024 | americanbankingnews.comBrady W. Dougan Sells 252,676 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockAugust 27, 2024 | markets.businessinsider.comBuy Rating Justified for HUMA: Strong Clinical Performance and Humanitarian Success in UkraineAugust 27, 2024 | uk.finance.yahoo.comHumacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian ProgramAugust 27, 2024 | stockhouse.comHumacyte Presents Positive Long-Term Results of ATEV(TM) in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian ProgramAugust 15, 2024 | msn.comSmall Cap Stocks: FDA Delay Created Buy-On-The-Dip Opportunity for Humacyte (HUMA)August 14, 2024 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | bizjournals.comDurham biotech could face months-long wait on FDA rulingAugust 13, 2024 | markets.businessinsider.comHumacyte Second Quarter 2024 Financial Results and Business UpdateAugust 13, 2024 | seekingalpha.comHumacyte, Inc. (HUMA) Q2 2024 Earnings Call TranscriptSee More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$8.60 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+63.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-942.81% Return on Assets-79.04% Debt Debt-to-Equity Ratio0.61 Current Ratio5.41 Quick Ratio5.41 Sales & Book Value Annual Sales$1.57 million Price / Sales399.73 Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-21.96Miscellaneous Outstanding Shares119,084,000Free Float91,576,000Market Cap$627.57 million OptionableOptionable Beta1.47 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 61)Ph.D., Founder, President, CEO & Director Comp: $899.25kMr. Dale A. Sander (Age 64)CFO, Chief Corporate Development Officer & Treasurer Comp: $704.33kDr. Heather Ledbetter Prichard Ph.D. (Age 46)Chief Operating Officer Comp: $647.78kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 52)Chief Commercial Officer Dr. Shamik J. Parikh M.D. (Age 51)Chief Medical Officer Comp: $514.72kMr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 58)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsEvolv TechnologiesNASDAQ:EVLVDasekeNASDAQ:DSKEBARKNYSE:BARKSystem1NYSE:SSTBeachbodyNYSE:BODYView All CompetitorsInsiders & InstitutionsBrady W DouganSold 352,112 sharesTotal: $2.24 M ($6.35/share)Laura E NiklasonSold 277,090 sharesTotal: $1.79 M ($6.47/share)Brady W DouganSold 252,676 sharesTotal: $1.70 M ($6.71/share)Dale A SanderSold 39,389 sharesTotal: $263,118.52 ($6.68/share)Millennium Management LLCBought 1,334,641 shares on 8/15/2024Ownership: 1.343%View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $2.84 on January 1st, 2024. Since then, HUMA stock has increased by 85.6% and is now trading at $5.27. View the best growth stocks for 2024 here. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. Who are Humacyte's major shareholders? Top institutional investors of Humacyte include Millennium Management LLC (1.34%), Renaissance Technologies LLC (0.50%), Marshall Wace LLP (0.39%) and Private Advisor Group LLC (0.31%). Insiders that own company stock include Laura E Niklason, Brady W Dougan, Gordon M Binder, William John Scheessele, Michael T Constantino, Heather Ledbetter Prichard and Dale A Sander. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts